clinical trial · NCT03050476
Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase
Alloksys Life Sciences B.V.·phase3·recruiting·n = 1,250
Systemic InflammationCardiopulmonary-bypassRESCAP®placebo
brief summary
Study should demonstrate that alkaline phosphatase reduces the incidence and extent of acute kidney injury after cardiopulmonary bypass (CPB) as defined by the AKIN criteria.
started
Nov 1, 2017
primary completion
Sep 30, 2025
completion
Mar 31, 2026
last updated
Apr 19, 2024
detailed description
After cardiac surgery under cardiopulmonary bypass (CPB) patients often show impairments of the immune system. Compared to placebo, CPB patients given alkaline phosphatase will have reduced composite endpoint of acute kidney injury (AKI), late extubation, gastrointestinal or neurological complications within 7 days and AKI within 90 days.
official title
Preventing Oxidative Stress-induced Ischemic Injury- and Systemic Inflammation Complications During and After Invasive Cardiac Surgery With Alkaline Phosphatase (APPIRED III)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol